FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4243493878> ?p ?o ?g. }

• W4243493878 endingPage "49" @default.
• W4243493878 startingPage "38" @default.
• W4243493878 abstract "Advances in the Treatment of Chronic Myeloid Leukemia Molecular monitoringMartin C Müller, Christian Dietz & Benjamin HanfsteinMartin C MüllerMartin C Müller is Professor and Specialist in Internal Medicine and Hematology/Oncology at the University Hospital of Mannheim, Heidelberg University, Germany. Having research interests in mechanisms of response and resistance to therapy as well as the monitoring of residual disease in chronic myeloid leukemia, he has been the author/coauthor of more than 70 peer-reviewed publications. He is responsible for the outpatient care of chronic myeloid leukemia patients and is Head of the Molecular Laboratory.Search for more papers by this author, Christian DietzChristian Dietz received his PhD degree in biology from the Heidelberg University in 2011. He started as Project Manager in the Clinical Trial Center at the Department of Hematology and Oncology at the University Medical Center Mannheim, Heidelberg University. Furthermore, he is the responsible Laboratory Manager and Quality Management Officer in the Molecular Laboratory at Heidelberg University.Search for more papers by this author & Benjamin HanfsteinBenjamin Hanfstein is Investigator of numerous clinical trials at the Chronic Myeloid Leukemia Center, University Hospital of Mannheim, Heidelberg University. Responsible for molecular monitoring of patients on tyrosine kinase inhibitor treatment, he gathered outstanding experience in PCR methods and mutational analysis. His vivid research interest is focused on genetic markers and their kinetics for early identification of treatment failures.Search for more papers by this authorPublished Online:22 Jul 2013https://doi.org/10.2217/ebo.13.179AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInReddit View chapterAbstract: The introduction of tyrosine kinase inhibitors as standard treatment of chronic myeloid leukemia was paralleled by the establishment of molecular diagnostics to routinely assess the activity of disease. The quantitative measurement of the BCR-ABL oncogene levels allows the exact determination of the individual treatment response, which correlates with prognosis and makes chronic myeloid leukemia a disease that is manageable like few others. PCR diagnostics can be performed from blood samples and surpass the sensitivity of conventional cytogenetics, which is of particular importance since the majority of patients today achieve very deep responses. In case of resistance, the detection of BCR-ABL mutations has become the major tool to guide second-line tyrosine kinase inhibitor treatment. References1 Hehlmann R , Hochhaus A , Baccarani M . Chronic myeloid leukaemia . Lancet 370 (9584) , 342 – 350 (2007) . Crossref, Medline, CAS, Google Scholar2 Cross NC , Melo JV , Feng L , Goldman JM . An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders . Leukemia 8 (1) , 186 – 189 (1994) . Medline, CAS, Google Scholar3 Deininger MW , Goldman JM , Melo JV . The molecular biology of chronic myeloid leukemia . Blood 96 (10) , 3343 – 3356 (2000) . Crossref, Medline, CAS, Google Scholar4 Hochhaus A , Reiter A , Skladny H et al. A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia . Blood 88 (6) , 2236 – 2240 (1996) . Crossref, Medline, CAS, Google Scholar5 Cross NC , White HE , Müller MC , Saglio G , Hochhaus A . Standardized definitions of molecular response in chronic myeloid leukemia . Leukemia 26 (10) , 2172 – 2175 (2012) . Crossref, Medline, CAS, Google Scholar6 Emig M , Saussele S , Wittor H et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR . Leukemia 13 (11) , 1825 – 1832 (1999) . Crossref, Medline, CAS, Google Scholar7 Branford S , Rudzki Z , Harper A et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase . Leukemia 17 (12) , 2401 – 2409 (2003) . Crossref, Medline, CAS, Google Scholar8 Baccarani M , Cortes J , Pane F et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet . J. Clin. Oncol. 27 (35) , 6041 – 6051 (2009) . Crossref, Medline, CAS, Google Scholar9 Sobrinho-Simoes M , Wilczek V , Score J , Cross NC , Apperley JF , Melo JV . In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib . Blood 116 (8) , 1329 – 1335 (2010) . Crossref, Medline, CAS, Google Scholar10 Kiss TL , Xu WM , Jamal N , Messner HA . Comparative testing of peripheral blood and bone marrow for BCR-ABL transcripts in patients post allogeneic bone marrow transplantation and during interferon treatment for chronic myeloid leukemia . Leuk. Lymphoma 34 (5–6) , 493 – 500 (1999) . Crossref, Medline, CAS, Google Scholar11 Thorn I , Olsson-Stromberg U , Ohlsen C et al. The impact of RNA stabilization on minimal residual disease assessment in chronic myeloid leukemia . Haematologica 90 (11) , 1471 – 1476 (2005) . Medline, Google Scholar12 Müller MC , Hordt T , Paschka P et al. Standardization of preanalytical factors for minimal residual disease analysis in chronic myelogenous leukemia . Acta Haematol. 112 (1–2) , 30 – 33 (2004) . Crossref, Medline, Google Scholar13 Beillard E , Pallisgaard N , Van Der Velden VH et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program . Leukemia 17 (12) , 2474 – 2486 (2003) . Crossref, Medline, CAS, Google Scholar14 Hughes TP , Kaeda J , Branford S et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia . N. Engl. J. Med. 349 (15) , 1423 – 1432 (2003) . Crossref, Medline, CAS, Google Scholar15 Hughes T , Deininger M , Hochhaus A et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results . Blood 108 (1) , 28 – 37 (2006) . Crossref, Medline, CAS, Google Scholar16 Branford S , Fletcher L , Cross NC et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials . Blood 112 (8) , 3330 – 3338 (2008) . Crossref, Medline, CAS, Google Scholar17 Müller MC , Cross NC , Erben P et al. Harmonization of molecular monitoring of CML therapy in Europe . Leukemia 23 (11) , 1957 – 1963 (2009) . Crossref, Medline, CAS, Google Scholar18 White HE , Matejtschuk P , Rigsby P et al. Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA . Blood 116 (22) , e111 – e117 (2010) . Crossref, Medline, CAS, Google Scholar19 Müller MC , Munjal U , Erben P et al. Stability of conversion factors for BCR-ABL monitoring – implications for the frequency of validation rounds . Blood 116 (21) , 893 (2010) . Crossref, Medline, Google Scholar20 Hughes TP , Hochhaus A , Branford S et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS) . Blood 116 (19) , 3758 – 3765 (2010) . Crossref, Medline, CAS, Google Scholar21 Hehlmann R , Lauseker M , Jung-Munkwitz S et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-{alpha} in newly diagnosed chronic myeloid leukemia . J. Clin. Oncol. 29 (12) , 1634 – 1642 (2011) . Crossref, Medline, CAS, Google Scholar22 Hanfstein B , Müller MC , Hehlmann R et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML) . Leukemia 26 (9) , 2096 – 2102 (2012) . Crossref, Medline, CAS, Google Scholar23 Marin D , Ibrahim AR , Lucas C et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors . J. Clin. Oncol. 30 (3) , 232 – 238 (2012) . Crossref, Medline, CAS, Google Scholar24 Hochhaus A , Boqué C , Bradley-Garelik MB . Molecular response kinetics and BCR-ABL reduction in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib vs imatinib: DASISION 3-year follow-up . Haematologica 97 (Suppl. 1) , Abstract 0192 (2012) . Google Scholar25 Hochhaus A , Guilhot F , Al-Ali K , Rosti G . Early BCR-ABL transcript levels predict future molecular response and long-term outcomes in newly-diagnosed patients with chronic myeloid leukemia in chronic phase: analysis of ENESTnd 3-year data . Haematologica 97 (Suppl. 1) , Abstract 0584 (2012) . Google Scholar26 Mahon FX , Rea D , Guilhot J et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial . Lancet Oncol. 11 (11) , 1029 – 1035 (2010) . Crossref, Medline, CAS, Google Scholar27 Hochhaus A , La Rosee P , Müller MC , Ernst T , Cross NC . Impact of BCR-ABL mutations on patients with chronic myeloid leukemia . Cell Cycle 10 (2) , 250 – 260 (2011) . Crossref, Medline, CAS, Google Scholar28 Branford S , Rudzki Z , Parkinson I et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations . Blood 104 (9) , 2926 – 2932 (2004) . Crossref, Medline, CAS, Google Scholar29 Press RD , Willis SG , Laudadio J , Mauro MJ , Deininger MW . Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib . Blood 114 (13) , 2598 – 2605 (2009) . Crossref, Medline, CAS, Google Scholar30 Soverini S , Hochhaus A , Nicolini FE et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet . Blood 118 (5) , 1208 – 1215 (2011) . Crossref, Medline, CAS, Google Scholar31 Parker WT , Lawrence RM , Ho M et al. Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy . J. Clin. Oncol. 29 (32) , 4250 – 4259 (2011) . Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Advances in the Treatment of Chronic Myeloid LeukemiaMetrics Downloaded 12 times History Published online 22 July 2013 Published in print July 2013 Information© Future Medicine Ltd© Future Medicine LtdPDF download" @default.
• W4243493878 created "2022-05-12" @default.
• W4243493878 creator A5040985262 @default.
• W4243493878 creator A5088450042 @default.
• W4243493878 creator A5091231607 @default.
• W4243493878 date "2013-07-01" @default.
• W4243493878 modified "2023-09-25" @default.
• W4243493878 title "Molecular monitoring" @default.
• W4243493878 cites W145991340 @default.
• W4243493878 cites W1971651191 @default.
• W4243493878 cites W1971880154 @default.
• W4243493878 cites W1981809014 @default.
• W4243493878 cites W1988399039 @default.
• W4243493878 cites W2002904896 @default.
• W4243493878 cites W2006112257 @default.
• W4243493878 cites W2016656445 @default.
• W4243493878 cites W2016809033 @default.
• W4243493878 cites W2021648831 @default.
• W4243493878 cites W2042929043 @default.
• W4243493878 cites W2048228382 @default.
• W4243493878 cites W2057827171 @default.
• W4243493878 cites W2068645465 @default.
• W4243493878 cites W2074301005 @default.
• W4243493878 cites W2079517811 @default.
• W4243493878 cites W2096894110 @default.
• W4243493878 cites W2105783133 @default.
• W4243493878 cites W2106266094 @default.
• W4243493878 cites W2117356576 @default.
• W4243493878 cites W2125690817 @default.
• W4243493878 cites W2140191827 @default.
• W4243493878 cites W2141324982 @default.
• W4243493878 cites W2148743957 @default.
• W4243493878 cites W2166641737 @default.
• W4243493878 cites W2166654361 @default.
• W4243493878 cites W2980284586 @default.
• W4243493878 doi "https://doi.org/10.2217/ebo.13.179" @default.
• W4243493878 hasPublicationYear "2013" @default.
• W4243493878 type Work @default.
• W4243493878 citedByCount "0" @default.
• W4243493878 crossrefType "other" @default.
• W4243493878 hasAuthorship W4243493878A5040985262 @default.
• W4243493878 hasAuthorship W4243493878A5088450042 @default.
• W4243493878 hasAuthorship W4243493878A5091231607 @default.
• W4243493878 hasConcept C41008148 @default.
• W4243493878 hasConcept C70721500 @default.
• W4243493878 hasConcept C86803240 @default.
• W4243493878 hasConceptScore W4243493878C41008148 @default.
• W4243493878 hasConceptScore W4243493878C70721500 @default.
• W4243493878 hasConceptScore W4243493878C86803240 @default.
• W4243493878 hasLocation W42434938781 @default.
• W4243493878 hasOpenAccess W4243493878 @default.
• W4243493878 hasPrimaryLocation W42434938781 @default.
• W4243493878 hasRelatedWork W2096946506 @default.
• W4243493878 hasRelatedWork W2130043461 @default.
• W4243493878 hasRelatedWork W2350741829 @default.
• W4243493878 hasRelatedWork W2358668433 @default.
• W4243493878 hasRelatedWork W2376932109 @default.
• W4243493878 hasRelatedWork W2382290278 @default.
• W4243493878 hasRelatedWork W2390279801 @default.
• W4243493878 hasRelatedWork W2748952813 @default.
• W4243493878 hasRelatedWork W2899084033 @default.
• W4243493878 hasRelatedWork W3004735627 @default.
• W4243493878 isParatext "false" @default.
• W4243493878 isRetracted "false" @default.
• W4243493878 workType "other" @default.